Company Overview: Inovio

Industry News

18 Jul

Inovio Announces Proposed Public Offering of Common Stock

PLYMOUTH MEETING, Pa., July 18, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that it intends to offer and sell $75.0 million of shares of its common stock in an underwritten public offering.  Inovio expects to grant the underwriters an option to purchase up to an additional...

Read more

28 Jun

Inovio Announces Leadership Appointments

PLYMOUTH MEETING, Pa., June 28, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced leadership appointments to support its growth and expanding strategic and operational initiatives. Inovio promoted Dr. Keiko Simon to Vice President, Alliance and Program Management and Jeffrey C. Richardson to Vice President, Strategic Relations. Dr....

Read more

15 Jun

Inovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution

PLYMOUTH MEETING, Pa., June 15, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that it has completed enrollment of its phase 1 clinical trial in Puerto Rico evaluating its Zika vaccine, GLS-5700. Inovio is developing this vaccine with GeneOne Life Science, Inc. (KSE:011000) and academic collaborators from the US...

Read more

1 Jun

Inovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 Checkpoint Inhibitor

PLYMOUTH MEETING, Pa., June 01, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced a clinical collaboration with Genentech, a member of the Roche Group, for advanced bladder cancer. The phase 1b/2 immuno-oncology trial will evaluate Genentech’s atezolizumab (TECENTRIQ®) in combination with Inovio’s INO-5401, a T cell activating...

Read more

24 May

Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study

PLYMOUTH MEETING, Pa., May 24, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP, consists of...

Read more

10 May

Inovio Pharmaceuticals Reports 2017 First Quarter Financial Results

PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today reported financial results for the quarter ended March 31, 2017. Total revenue was $10.4 million for the three months ended March 31, 2017, compared to $8.1 million for the same period in 2016. Total operating...

Read more

10 May

Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer

PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced MedImmune, AstraZeneca’s global biologics research and development arm, will start a new clinical trial investigating the combination of MEDI0457, an immunotherapy designed to generate antigen specific killer T cell responses targeting HPV-associated tumors, and...

Read more

Page 1 of 1212345...10...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address